Johnson & Johnson Reports Strong Q4 2025 Results, Faces Ongoing Talc Litigation Challenges

Johnson & Johnson reported robust fourth-quarter 2025 earnings that surpassed analyst expectations, with the company's stock gaining significantly following the results. The pharmaceutical giant reported adjusted earnings of $2.46 per share, exceeding the consensus estimate of $2.43, and sales of $24.56 billion, also beating the $24.12 billion consensus. Sales increased 9.1% year-over-year, with an operational increase of 7.1%.

The company provided an optimistic outlook for 2026, projecting sales between $100.0 billion and $101.0 billion, representing 6.2%-7.2% growth, and adjusted EPS around $11.53, a 6.9% increase at the midpoint, which exceeded average analyst forecasts. Full year 2025 revenue of $94.2 billion grew 6% operationally, with gross profit of $64.1 billion at 68% margins and operating income of $26.3 billion at 28% margins.

Despite the impact of Stelara's loss of exclusivity, which reduced revenue growth by 650 basis points in Q4 2025, Johnson & Johnson's Innovative Medicines segment demonstrated strong performance with a 10.0% year-over-year sales increase to $15.76 billion. This growth was fueled by strong sales of key products such as Darzalex, which achieved $3.9 billion in Q4 2025 sales and crossed $14 billion in annual revenue, and Carvykti, with Q4 sales soaring 66% to $555 million. Tecvayli also saw a 21% rise in sales to $176 million in the same quarter.

Significant regulatory approvals, including Caplyta for major depressive disorder in November 2025 and nipocalimab (Imaavy) for generalized myasthenia gravis late in 2025, with projected peak sales exceeding $5 billion, further boosted investor confidence in the company's pipeline. The company received FDA Breakthrough Therapy Designation on February 18, 2026, for RYBREVANT FASPRO as monotherapy in HPV-unrelated head and neck squamous cell carcinoma, adding to a pipeline that secured 51 regulatory approvals and 32 submissions in 2025 alone.

In March 2026, Johnson & Johnson reported new 52-week Phase 3 ICONIC data showing ICOTYDE, its recently FDA‑approved oral IL‑23 receptor blocker for moderate‑to‑severe plaque psoriasis, maintained strong efficacy and a consistent safety profile in adults and adolescents. The trials not only confirmed durable skin clearance but also indicated lower overall adverse event and infection rates versus deucravacitinib through Week 24.

However, the company faces escalating legal challenges. Johnson & Johnson lost its second consecutive talc trial on February 13, 2026, with a Philadelphia jury awarding $250,000 to the Gayle Emerson estate, following a $40 million California verdict in December 2025. The company now faces over 67,000 active lawsuits after three failed bankruptcy attempts and a January 2026 federal ruling allowing plaintiffs' expert testimony linking baby powder to ovarian cancer.

Free cash flow of $19.7 billion in 2025 is guided to rise to $21 billion in 2026, while the planned Orthopaedics separation targeting mid-2027 will push the high-growth asset share of the MedTech portfolio from approximately 50% today to over 70%. The CEO stated that "we have line of sight to double-digit growth by the end of the decade, which is notable as Johnson & Johnson is the only health care company that will soon deliver more than $100 billion in annual revenue," a claim grounded in 13 pharmaceutical brands growing double digits in 2025 and 28 platforms each exceeding $1 billion in annual revenue.